Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05535660 · ClinicalTrials.gov registry record
Lipid Profile as Predictor of Adverse Maternal and Neonatal Outcomes: A Pilot Study
A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 111
- Enrollment target
NCT05535660: Completed study, sponsored by Icahn School of Medicine at Mount Sinai.
NCT05535660 is a clinical trial that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 111 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05535660 has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 111 participants
- Enrollment target
Study Summary
The purpose of this study is to ascertain lipid profiles during pregnancy, specifically during the 24-28 week gestation and again near term at 36 weeks gestation. The research team are investigating whether lipid profiles can predict adverse maternal and neonatal outcomes.
Primary Outcome
Neonatal birthweight will be classified as large for gestational age (LGA) or non-LGA
Interventions
- DIAGNOSTIC_TEST Lipid panel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2022-07-29 |
| Est. Completion | 2024-08-05 |
What the finished NCT05535660 record still lists
NCT05535660 is an observational study that tracks outcomes without assigning an intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Lipid panel is the first listed.
NCT05535660 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05535660 about?
NCT05535660 is a clinical study titled "Lipid Profile as Predictor of Adverse Maternal and Neonatal Outcomes: A Pilot Study". The purpose of this study is to ascertain lipid profiles during pregnancy, specifically during the 24-28 week gestation and again near term at 36 weeks gestation. The research team are investigating whether lipid profiles can predict adverse maternal and neonatal outcomes.
What is the current status of trial NCT05535660?
This trial is currently completed. The enrollment target is 111 participants. The study started on 2022-07-29. Estimated completion is 2024-08-05.
What interventions are being tested in trial NCT05535660?
The interventions under investigation include: Lipid panel (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05535660?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI